Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial

This trial tests rituximab (a drug that targets and removes a type of immune cell called B-cells) as an initial treatment for children newly diagnosed with nephrotic syndrome — a kidney condition where the kidneys leak large amounts of protein into the urine. Standard treatment involves steroids, but these have side effects and the condition often relapses. This study tests whether rituximab can achieve remission while reducing long-term steroid exposure. **Your child may be eligible if...** - They have been newly diagnosed with idiopathic (no clear cause) nephrotic syndrome - Their kidney filtering function is in the normal range **Your child may NOT be eligible if...** - They have blood in the urine, low complement levels, or persistent high blood pressure - Their nephrotic syndrome is caused by another condition (e.g., lupus, hepatitis B, diabetes) - They have other kidney diseases, a family history of inherited kidney disorders, or a genetic condition affecting the kidneys - They have an immune deficiency, active infection (including tuberculosis, hepatitis, HIV), or severe blood count abnormalities - They have received immunosuppressive drugs in the past 3 months - They are allergic to rituximab - They received a live vaccine within the past month Talk to your doctor to see if this trial is right for your child.